摘要：
As lncRNAs have increasingly been investigated, they are no longer simply defined as RNAs with no transcription capability. Studies have identified significant associations between the abnormal expression of lncRNAs and human diseases, particularly the mechanisms by which lncRNAs play a part in cancers, which are of considerable attention to researchers. As a result of the complex spatial structure, the mechanisms of interaction of lncRNAs in cancer cells are also complicated and diversified. Among a series of lncRNAs, TUG1, which is now considered to be a very high-value lncRNA, has recently been identified to express abnormally in some malignancies, leading to different alterations in cancer cells proliferation, migration, invasion, apoptosis, and drug resistance, and hence promoting or inhibiting cancer progression. Current studies have implicitly indicated that TUG1 can be used as a therapeutic target for human cancers. However, the biological functions of TUG1 have been studied for a short period of time, and the complete molecular mechanism still needs to be clarified. Accordingly, this review focuses on the principal molecular mechanisms of TUG1 in human cancers and the specific mechanisms of action in different cancer development processes based on existing studies.
期刊：
South Asian Journal of Cancer,2023年 ISSN：2278-330X
作者机构：
[Hui Hua; Xiaoyong Lei; Jia Yu; Xinxin Zhang] Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.
摘要：
<jats:p>No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.</jats:p>
作者机构：
[Zhang, Taolan; Li, Zhuo; Hu, Haihong; Zhan, Wendi; Lei, Xiaoyong; Zhu, Hongxia; Tang, Liyang] Univ South China, Hengyang Med Coll, Sch Pharm, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.;[Zhang, Taolan; Li, Zhuo; Hu, Haihong; Zhan, Wendi; Zhang, TL; Zhu, Hongxia; Tang, Liyang] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pharm, 69 Chuanshan Rd, Hengyang 421001, Hunan, Peoples R China.;[Zhang, Taolan; Li, Zhuo; Hu, Haihong; Zhan, Wendi; Zhu, Hongxia; Tang, Liyang] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Chinese Tradit Med TCM Res Platform Major Epidem T, 69 Chuanshan Rd, Hengyang 421001, Hunan, Peoples R China.
通讯机构：
[Zhang, TL ] U;Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pharm, 69 Chuanshan Rd, Hengyang 421001, Hunan, Peoples R China.
关键词：
Breast cancer;Fatty acid metabolism;Unsupervised clustering;Tumor immune microenvironment;Immunotherapy
摘要：
Breast cancer (BRCA) is a major global health issue, characterized by high mortality and low early diagnosis rates. The tumor immune microenvironment (TME) of BRCA is closely linked to fatty acid metabolism (FAM). This study aimed to identify FAM-related subtypes in BRCA based on gene expression and clinical data from the Cancer Genome Atlas (TCGA) database. The study found two distinct FAM-related subtypes, each with unique immune characteristics and prognostic implications. A FAM-related risk score prognostic model was developed and validated using TCGA and International Cancer Genome Consortium (GEO) cohorts, showing potential clinical applications for chemotherapy and immunotherapy. Additionally, a nomogram was established to facilitate clinical use of the risk score. These results highlight the significant correlation between FAM genes and TME in BRCA, and demonstrate the potential clinical utility of the FAM-related risk score in informing treatment decisions for BRCA patients.
摘要：
Multi-drug resistance (MDR) is characterized by the resistance of tumor cells to some antitumor drugs with different structures and mechanisms after the use of a single chemotherapy drug or even the first use of the drug. Notably, MDR has become the largest obstacle to the success of gastric cancer chemotherapies. Non-coding RNAs are defined as a class of RNAs that do not have the ability to code proteins. They are widely involved in important biological functions in life activities. Multiple lines of evidence demonstrated that ncRNAs are closely related to human cancers, including gastric cancer. However, the relationship between ncRNAs and MDR in gastric cancer has been reported, yet the mechanisms are not fully clarified. Therefore, in this review, we systematically summarized the detailed molecular mechanisms of lncRNAs (long noncoding RNAs) and miRNAs (microRNAs) associated with MDR in gastric cancer. Additionally, we speculate that the abnormal expression of ncRNAs is likely to be a novel potential therapeutic target reversing MDR for gastric cancer. Future therapeutics for gastric cancer will most likely be based on noncoding RNAs (ncRNAs) that regulate MDR-related genes.
摘要：
At present, the incidence of cancer is becoming more and more common, but its treatment has always been a problem. Although a small number of cancers can be treated, the recurrence rates are generally high and cannot be completely cured. At present, conventional cancer therapies mainly include chemotherapy and radiotherapy, which are the first-line therapies for most cancer patients, but there are palliatives. Approaches to cancer treatment are not as fast as cancer development. The current cancer treatments have not been effective in stopping the development of cancer, and cancer treatment needs to be imported into new strategies. Non-coding RNAs (ncRNAs) is a hot research topic at present. NcRNAs, which include microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs), participate in all aspects of cancer biology. They are involved in the progression of tumors into a new form, including B-cell lymphoma, glioma, or the parenchymal tumors such as gastric cancer and colon cancer, among others. NcRNAs target various immune checkpoints to affect tumor proliferation, differentiation, and development. This might represent a new strategy for cancer treatment.
期刊：
Scandinavian Journal of Immunology,2022年96(4) ISSN：0300-9475
通讯作者：
Xiaoyong Lei
作者机构：
[Yang, Xiaoyan; Liu, Daquan; Cao, Pu; Xie, Zhizhong; Lei, Xiaoyong; Ye, Simin; Yang, Wei] Univ South China, Hengyang Med Coll, Sch Pharm, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.;[Lei, Xiaoyong] Univ South China, Hunan Prov Key Lab Tumor Microenvironm Respons Dr, Hengyang, Hunan, Peoples R China.
通讯机构：
[Xiaoyong Lei] S;School of Pharmacy, Hengyang Medical College, University of South China, Hengyang, Hunan, China<&wdkj&>The Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, Hunan, China
摘要：
Cancer is the second leading cause of death among human diseases. Immunotherapy has opened a new chapter in cancer treatment. However, the emergence of immune escape mechanisms severely limited its application. The high expression of PD-L1 on tumour cells is an important means for cancer cells to achieve immune escape via binding to PD-1 on immune cells. Recent studies have shown that PD-L1 expression in most cancer cells is over-glycosylated. Glycosylation is a fundamental and extensive post-translational modification of eukaryotic membrane-binding proteins, which affects a variety of biological activities, including protein folding, solubility, stability and ligand-receptor interactions. PD-L1 glycosylation initiates in the endoplasmic reticulum (ER) and completes in the Golgi apparatus, which has a complex relationship with cancer development. Importantly, non-glycosylated PD-L1 attenuates protein stability and PD-1 interactions. These processes are essential regulatory mechanisms that modulate immunosuppression and immune surveillance in cancer patients. Therefore, non-glycosylated PD-L1 may be a potentially promising strategy to improve the efficacy of checkpoint blockade therapy for cancer. In this review, we have described the PD-L1 glycosylation processes and provided evidence for the role of non-glycosylated PD-L1 in anti-tumour-related signalling pathways. Furthermore, strategies for non-glycosylation of PD-L1 using small molecule inhibitors, gene therapy and various enzymes in the synthetic glycosylation pathway are discussed. Finally, the detection of PD-L1 expression is enhanced by its deglycosylation, and we have summarized the development, application and clinical application potential of antibody therapies targeting PD-1/PD-L1 glycosylation.
作者机构：
[Wen, Gebo; Yu, Jia] Univ South China, Canc Res Inst, Hengyang Med Coll, Hunan Prov Key Lab Tumor Cellular & Mol Pathol, Hengyang, Hunan, Peoples R China.;[Hu, Juan; Yang, Xiaoyan; Tan, Fang; Lei, Xiaoyong; Yao, Jinyu; Yu, Jia] Univ South China, Inst Pharm & Pharmacol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hunan Prov Key Lab Tumor Microenvironm Respons Dru, Hengyang, Hunan, Peoples R China.;[Zhang, Xinxin] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.;[He, Rongfang] Univ South China, Affiliated Hosp 1, Dept Pathol, Hengyang, Peoples R China.
通讯机构：
[Jia Yu; Xiaoyan Yang; Gebo Wen; Juan Hu; Jinyu Yao; Fang Tan; Xiaoyong Lei] H;[Xinxin Zhang] S;[Rongfang He] D;Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology,Cancer Research Institute,Hengyang Medical College,China<&wdkj&>Department of Pathology,The First Affiliated Hospital of University of South China,Hengyang,China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study,Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research,Institute of Pharmacy and Pharmacology,China<&wdkj&>State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center,Guangzhou,China<&wdkj&>Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology,Cancer Research Institute,Hengyang Medical College,China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study,Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research,Institute of Pharmacy and Pharmacology,China
关键词：
Introduction;Materials and Methods;Results;Discussion;Conclusion;Abstract;Data Availability;Additional Points;Ethical Approval;Consent;Disclosure;Conflicts of Interests;Authors’ Contributions;Funding Statement;Acknowledgements;Acknowledgments;Supplementary Materials;Reference;Dataset Description;Dataset Files;Abstract;Introduction;Introduction and Materials;Introduction and Methods;Materials;Materials and Methods;Methods;Results;Discussion;Results and Discussion;Discussion and Conclusion;Results and Conclusion;Conclusion;Conclusions;Data Availability;Additional Points;Ethical Approval;Consent;Disclosure;Conflicts of Interest;Authors’ Contributions;Funding Statement;Acknowledgements;Supplementary Materials;References;Appendix;Abbreviations;Preliminaries;Introduction and Preliminaries;Notation;Proof of Theorem;Proofs;Analysis of Results;Examples;Numerical Example;Applications;Numerical Simulation;Model;Model Formulation;Systematic Palaeontology;Nomenclatural Acts;Taxonomic Implications;Experimental;Synthesis;Overview;Characterization;Background;Experimental;Theories;Calculations;Model Verification;Model Implementation;Geographic location;Study Area;Geological setting;Data Collection;Field Testing;Data and Sampling;Dataset;Literature Review;Related Works;Related Work;System Model;Methods and Data;Experimental Results;Results and Analysis;Evaluation;Implementation;Case Presentation;Case Report;Search Terms;Case Description;Case Series;Background;Limitations;Additional Points;Case;Case 1;Case 2 etc.;Concern Details;Retraction Details;Copyright;Related Articles
摘要：
Chronic infection is considered a risk factor for atherosclerosis. The link between infectious agents and atherosclerosis is manifested by the presence of infection-induced pyroptotic cells in atherosclerotic lesions. Pyroptosis is an inflammatory form of programmed cell death that occurs most frequently upon infection. However, inflammation is not the only cause by which pyroptosis involved in atherosclerosis. During pyroptosis, a large amount of microparticles are released from pyroptotic cells, which not only transfer inflammatory mediators to arterial vessel, but also mediate the interaction between a variety of cells, leading to endothelial injury, macrophage infiltration, vascular smooth muscle cell migration and proliferation, thereby accelerating atherosclerosis. Thus, we proposed hypothesis that pyroptotic cell-derived microparticle is an atherogenic factor in infectious diseases.
摘要：
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Hepatocellular carcinoma (HCC) is a common type of cancer with a high
mortality rate and is usually detected at the middle or late stage, missing the optimal treatment period.
The current study aims to identify potential long non-coding RNA (lncRNAs) biomarkers that
contribute to the diagnosis and prognosis of HCC.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>The differentially expressed lncRNAs (DElncRNAs) in HCC patientsThe differentially expressed lncRNAs (DElncRNAs) in HCC patients were detected
from the Cancer Genome Atlas (TCGA) dataset. LncRNAs signature was screened by LASSO regression,
univariate, and multivariate Cox regression. The models for predicting diagnosis and
prognosis were established, respectively. The prognostic model was evaluated by Kaplan-Meier
survival curve receiver operating characteristic (ROC) curve and stratified analysis. The diagnostic
model was validated by ROC. The lncRNAs signature was further demonstrated by functional enrichment
analysis. were detected from the Cancer Genome Atlas (TCGA) dataset. LncRNAs signature was screened by LASSO regression, univariate and multivariate Cox regression.
The models for predicting diagnosis and prognosis were established respectively. The prognostic model was evaluated by
Kaplan-Meier survival curve receiver operating characteristic (ROC) curve and stratified analysis. The diagnostic model
was validated by ROC. The lncRNAs signature was further demonstrated by functional enrichment analysis.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>We found the 13-lncRNAs signature that had a good performance in predicting prognosis
and could help to improve the value of diagnosis. In the training set, testing set, and entire cohort,
the low-risk group had longer survival than the high-risk group (median OS: 3124 vs. 649 days,
2456 vs. 770 days and 3124 vs. 755 days). It performed well in 1-, 3-, and 5-year survival prediction.
13-lncRNAs-based risk score, age, and race were good predictors of prognosis. The AUC of
diagnosis was 0.9487, 0.9265, and 0.9376, respectively. Meanwhile, the 13-lncRNAs were involved
in important pathways, including the cell cycle and multiple metabolic pathways.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p> In our study, the 13-lncRNAs signature may be a potential marker for the prognosis
of HCC and improve the diagnosis.</jats:p>
</jats:sec>
期刊：
Drug Development Research,2021年82(1):108-114 ISSN：0272-4391
通讯作者：
Cao, Xuan;Xie, Zhi-Zhong
作者机构：
[Xie, Zhi-Zhong; Cao, Xuan; Xie, ZZ; Lei, Xiao-Yong; Tang, Guo-Tao; Qin, Chang-Feng; Ji, Tong-Ying; Qiu, Jin-Mei; Wu, Shen-Gen] Univ South China, Hunan Prov Key Lab Tumour Microenvironm Respons D, 28 Chang Sheng Rd, Hengyang City 421001, Hunan, Peoples R China.;[Xie, Zhi-Zhong] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China.
通讯机构：
[Cao, X; Xie, ZZ] U;Univ South China, Hunan Prov Key Lab Tumour Microenvironm Respons D, 28 Chang Sheng Rd, Hengyang City 421001, Hunan, Peoples R China.
关键词：
antioxidant;free radical scavenging ability;resveratrol;salvianolic acid A
摘要：
<jats:title>Abstract</jats:title><jats:p>E‐DRS is a novel salvianolic acid A (SAA) analog, which was synthesized from resveratrol (RES) and methyldopate. Its structure is similar to that of SAA, but the 3′,4′‐dihydroxy‐<jats:italic>trans</jats:italic>‐stilbene group and the ester structure in SAA were replaced by the RES structure and an amine group, respectively. E‐DRS scavenged free oxygen radicals effectively, including superoxide anion (ascorbic acid > E‐DRS > SAA ≥ rutin > RES) and DPPH radical (rutin > E‐DRS ≥ ascorbic acid > SAA > RES), and exhibited powerful total antioxidant capacity (ascorbic acid > E‐DRS > SAA ≥ rutin > RES) in vitro. Furthermore, oral administration of E‐DRS dose‐dependently and significantly decreased CCl<jats:sub>4</jats:sub>‐induced oxidative stress in mice as indicated by the decreased content of hepatic malondialdehyde (MDA). In addition, oral administration of E‐DRS also increased the content of nonenzymatic antioxidant glutathione (GSH) and the activity of antioxidant enzymes such as catalase (CAT) and superoxide dismutase (SOD) in the liver of mice. All these results demonstrated that E‐DRS had good antioxidant activities both in vitro and in vivo, and could be a potential antioxidant agent after further optimization and evaluation.</jats:p>
摘要：
<jats:title>Abstract</jats:title><jats:p>A series of compounds bearing 3′,4′,5′‐trimethoxy module into the core structure of evodiamine were designed and synthesized. The synthesized compounds were screened in vitro for their antitumor potential. MTT results showed that compounds <jats:bold>14a–14c</jats:bold> and <jats:bold>14i–14j</jats:bold> had significant effects, with compound <jats:bold>14h</jats:bold> being the most prominent, with an IC<jats:sub>50</jats:sub> value of 3.3 ± 1.5μM, which was lower than evodiamine and 5‐Fu. Subsequent experiments further confirmed that compound <jats:bold>14h</jats:bold> could inhibit cell proliferation and migration, and induce G2/M phase arrest to inhibit the proliferation of HGC‐27 cells, which is consistent with the results of the cytotoxicity experiment. Besides, <jats:bold>14h</jats:bold> could inhibit microtubule assembly and might kill tumor cells by inhibiting VEGF and glycolysis. All experimental results indicate that compound <jats:bold>14h</jats:bold> might be a potential drug candidate for the treatment of gastric cancer and was worthy of further study.</jats:p>
作者机构：
[Gan, Runliang; Yang, Xiaoyan] Univ South China, Hengyang Med Coll, Canc Res Inst, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.;[Yang, Xiaoyan; Xie, Zhizhong; Lei, Xiaoyong] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Hunan, Peoples R China.;[Yang, Xiaoyan; Xie, Zhizhong; Lei, Xiaoyong] Univ South China, Inst Pharm & Pharmacol, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
通讯机构：
[Gan, Runliang; Lei, Xiaoyong] U;Univ South China, Hengyang Med Coll, Canc Res Inst, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.;Univ South China, Inst Pharm & Pharmacol, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
期刊：
International Journal of Cancer,2019年144(3):651-664 ISSN：0020-7136
通讯作者：
Zu, Xuyu;Jiang, Yuyang
作者机构：
[Zhong, Jing; Zu, Xuyu; Cao, Renxian; Peng, Xiuda; Liu, Jianghua; Ding, Wenjun; Shen, Yingying] Univ South China, Inst Clin Med, Affiliated Hosp 1, 69 Chuanshan Rd, Hengyang 421001, Hunan, Peoples R China.;[Zhang, Wei] Tsinghua Univ, Sch Med, Dept Biol, Beijing, Peoples R China.;[Cao, Renxian; Liu, Jianghua] Univ South China, Affiliated Hosp 1, Dept Metab & Endocrinol, Hengyang, Hunan, Peoples R China.;[He, Jun] Univ South China, Affiliated Hosp 1, Dept Spine Surg, Hengyang, Hunan, Peoples R China.;[Chen, Xiguang] Univ South China, Affiliated Hosp 1, Dept Med Oncol, Hengyang, Hunan, Peoples R China.
通讯机构：
[Zu, Xuyu] U;[Jiang, Yuyang] T;Univ South China, Inst Clin Med, Affiliated Hosp 1, 69 Chuanshan Rd, Hengyang 421001, Hunan, Peoples R China.;Tsinghua Univ, Grad Sch Shenzhen, Guangdong Prov Key Lab Chem Biol, Lishui Rd, Shenzhen 518055, Peoples R China.
关键词：
*AXL;*DCC-2036;*MET;*PDX;*TNBC
摘要：
Triple-negative breast cancer (TNBC) is insensitive to endocrine therapies and targeted therapies to human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor (PR). New targets and new targeted therapeutic drugs for TNBC are desperately needed. Our study confirmed that DCC-2036 inhibited the proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) of TNBC cells as well as induced apoptosis. Moreover, the antiproliferative activity of DCC-2036 was more efficient than that of most clinical drugs. In addition, the combination of DCC-2036 and cisplatin or lapatinib had synergistic effects on TNBC cells. Mechanistically, DCC-2036 targeted AXL/MET, especially AXL, and regulated the downstream PI3K/Akt-NFkappaB signaling to exert its antitumor effect in TNBC. DCC-2036 also inhibited the growth and metastasis of xenografted MDA-MB-231 cells (AXL/MET-high TNBC cells) but not MDA-MB-468 cells (AXL-low TNBC cells) in NSG mice in vivo. Furthermore, DCC-2036 significantly inhibited tumor growth and invasion of AXL/MET-high TNBC PDX tumors but not AXL/MET-low TNBC PDX tumors. These results highlighted the roles of AXL/MET in cancer growth and metastasis and further verified that the critical targets of DCC-2036 are AXL and MET, especially AXL. In addition, there was no significant toxicity of DCC-2036 even at a high dosage. Therefore, DCC-2036 may be a potential compound to treat TNBC, especially for tumors with AXL/MET overexpression.
